Endo Must Shed Drugs For $225M Boca Buy, FTC Says

Law360, New York (January 31, 2014, 2:33 PM EST) -- The Federal Trade Commission on Friday ordered Endo Health Solutions Inc. to sell three generic drugs in development and give up the right to sell four generic vitamin drops in order to win clearance for its $225 million acquisition of Boca Pharmacal LLC.

The deal Pennsylvania-based Endo reached with the FTC requires the company to relinquish Boca's exclusive marketing and distribution rights to four prescription generic multivitamin drops with fluoride for children. The proposed consent order also calls for Endo to sell three other generic drugs...
To view the full article, register now.